Research and Markets: Competitor Analysis: Enzyme Replacement Therapies

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3pbfzv/competitor) has announced the addition of the "Competitor Analysis: Enzyme Replacement Therapies" report to their offering.

The Competitive Intelligence Report Enzyme Replacement & Enhancement Therapies (ERT) as of January 2013 provides a competitor analysis in the development pipeline of novel enzyme replacement therapies and of enzyme enhancement therapies to treat human genetic diseases/lysosomal storage diseases and exocrine pancreatic insufficiency due to cystic fibrosis, pancreatitis and other causes.

The report includes a compilation of current active projects in research and development of novel enzyme replacement & enhancement therapy products and an overview of approved products. In addition, the report lists company-specific product portfolios and R&D pipelines of enzyme replacement and enhancement therapies. Competitor projects are listed in a tabular format providing Information on:

- Drug Codes,

- Target / Mechanism of Action,

- Class of Compound,

- Company,

- Product Category,

- Indication,

- R&D Stage and

- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Key Topics Covered

1. Enzyme Replacement Therapies

Gaucher Disease

Fabry Disease

Pompé Disease

Hunter Disease (MPS II)

Niemann Pick Diseases

Mucopolysaccharidosis I (MPS I)

San Filippo Syndrome (MPS IIIA)

Morquio Syndrome (MPS IVA)

Mucopolysaccharidosis VI (MPS VI)

Tay-Sachs Disease

Chronic Deficiency of Adenosine Deaminase

Phenylketonuria / Hyperphenylalaninemia

Other Enzyme Replacement Therapies

Exocrine Pancreatic Insufficiency: Porcine-Derived ERT

Exocrine Pancreatic Insufficiency: Recombinant ERT

2. Corporate Enzyme Replacement Therapies R&D Pipelines

Examples of Companies Mentioned

- Abbott

- Angiochem

- Aptalis Pharma

- Asubio Pharma

- Axcan Pharma

- BioMarin

- Bionaturis

- Digestive Care

- Dong-A Pharmaceuticals

- Eli LIlly

- ExSar

- GlaxoSmithKline (GSK)

- ISU Abxis

- JCR Pharmaceuticals

- Johnson & Johnson

- Kissei Pharmaceuticals

- Mayoly-Spindler

- Merck Serono

- Nycomed

- Orphan Technologies

- Orphazyme

- Pfizer

- Protea Biosciences

- Recordati

- ReGenX Biosciences

- Sanofi

- Shire

- Sigma-Tau

- Swedish Orphan Biovitrum

- Synageva

- Ultragenyx Pharmaceutical

- Vivendy Therapeutics

- Zymenex

For more information visit http://www.researchandmarkets.com/research/3pbfzv/competitor